Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) FCF Margin (2021 - 2026)

Kiniksa Pharmaceuticals International filings provide 6 years of FCF Margin readings, the most recent being 23.38% for Q1 2026.

  • On a quarterly basis, FCF Margin rose 720.0% to 23.38% in Q1 2026 year-over-year; TTM through Mar 2026 was 21.98%, a 1284.0% increase, with the full-year FY2025 number at 20.35%, up 1432.0% from a year prior.
  • FCF Margin hit 23.38% in Q1 2026 for Kiniksa Pharmaceuticals International, down from 27.08% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 62.57% in Q3 2022 to a low of 114.47% in Q1 2022.
  • Median FCF Margin over the past 5 years was 7.78% (2022), compared with a mean of 4.04%.
  • Biggest five-year swings in FCF Margin: skyrocketed 47517bps in 2022 and later plummeted -3726bps in 2023.
  • Kiniksa Pharmaceuticals International's FCF Margin stood at 7.78% in 2022, then crashed by -34bps to 5.12% in 2023, then surged by 198bps to 15.26% in 2024, then surged by 77bps to 27.08% in 2025, then fell by -14bps to 23.38% in 2026.
  • The last three reported values for FCF Margin were 23.38% (Q1 2026), 27.08% (Q4 2025), and 18.29% (Q3 2025) per Business Quant data.